On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is...Show More

On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is actively soliciting votes and encourages stockholders to review the proxy statement and vote if they have not already done so. The company also announced that its current cash and cash equivalents are expected to sustain operations through mid-February 2024 and it continues to explore strategic or financing alternatives. As of the record date, NexImmune had 1,058,125 shares of common stock issued and outstanding.